Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
Tianyu Tang(First Affiliated Hospital Zhejiang University), Tingbo Liang(Zhejiang University)
Cited by 594
Related Papers
Oncolytic virotherapy: basic principles, recent advances and future directions
|Signal Transduction and Targeted Therapy|2023|386
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
|The Lancet Oncology|2023|243
mRNA vaccines in disease prevention and treatment
|Signal Transduction and Targeted Therapy|2023|217